WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Ingo Hardt
Partner
Patents and Innovations
San Diego
ihardt@wsgr.com

D858-350-2352

Download vCard
Open PDF

Dr. Ingo Hardt is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology. He has been a registered patent agent since 2003.

Prior to joining the firm, Ingo worked as a scientist for Pfizer Animal Health in the United Kingdom and DuPont Pharmaceuticals and Pfizer in San Diego. During his tenure in the pharmaceutical industry, Ingo filled a variety of roles in analytical technology development, pharmaceutical sciences, regulatory CMC, and project management. He also served as a leader of analytical and natural products groups with responsibility for ensuring the quality of clinical-trial materials and the structure elucidation of impurities, degradants, and natural products.

Ingo is an author or co-author of 20 peer-reviewed scientific articles, as well as a co-inventor on two issued U.S. patents.

Ingo is fluent in German.

Experience

Dr. Ingo Hardt is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology. He has been a registered patent agent since 2003.

Prior to joining the firm, Ingo worked as a scientist for Pfizer Animal Health in the United Kingdom and DuPont Pharmaceuticals and Pfizer in San Diego. During his tenure in the pharmaceutical industry, Ingo filled a variety of roles in analytical technology development, pharmaceutical sciences, regulatory CMC, and project management. He also served as a leader of analytical and natural products groups with responsibility for ensuring the quality of clinical-trial materials and the structure elucidation of impurities, degradants, and natural products.

Ingo is an author or co-author of 20 peer-reviewed scientific articles, as well as a co-inventor on two issued U.S. patents.

Ingo is fluent in German.

Education
  • J.D., University of San Diego School of Law, 2011Magna Cum Laude; Order of the Coif; Member, San Diego Law Review
  • Dr. rer. nat. (Ph.D.), Organic Chemistry, University of Hamburg, Germany, 1994
  • Dipl.-Chem. (M.S.), Chemistry, University of Hamburg, Germany, 1992
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., University of San Diego School of Law, 2011Magna Cum Laude; Order of the Coif; Member, San Diego Law Review
  • Dr. rer. nat. (Ph.D.), Organic Chemistry, University of Hamburg, Germany, 1994
  • Dipl.-Chem. (M.S.), Chemistry, University of Hamburg, Germany, 1992
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author, "Toward the Development of a Structurally Novel Class of Chiral Auxiliaries. Conformational Properties of the Aldol Adducts of Oxadiazinones: Observation of Unusual Shielding Effects," 69(3) Journal of Organic Chemistry 727-734, 2004
  • Co-author, "Mass-directed fractionation and isolation of pharmaceutical compounds by packed-column supercritical fluid chromatography/mass spectrometry," 15 Rapid Communications in Mass Spectrometry 2067-2075, 2001
  • Co-author, "Natural Epothilones from Sorangium cellulosum, Strains So ce90/B2 and So ce90/D13: Isolation, Structure Elucidation, and SAR Studies," 64 Journal of Natural Products 847-856, 2001
  • Co-author, "Optically Active Reference Compounds for Environmental Analysis Obtained by Preparative Enantioselective Gas Chromatography," 33 Angewandte Chemie International Edition 2085-2087, 1994
Insights

Select Publications

  • Co-author, "Toward the Development of a Structurally Novel Class of Chiral Auxiliaries. Conformational Properties of the Aldol Adducts of Oxadiazinones: Observation of Unusual Shielding Effects," 69(3) Journal of Organic Chemistry 727-734, 2004
  • Co-author, "Mass-directed fractionation and isolation of pharmaceutical compounds by packed-column supercritical fluid chromatography/mass spectrometry," 15 Rapid Communications in Mass Spectrometry 2067-2075, 2001
  • Co-author, "Natural Epothilones from Sorangium cellulosum, Strains So ce90/B2 and So ce90/D13: Isolation, Structure Elucidation, and SAR Studies," 64 Journal of Natural Products 847-856, 2001
  • Co-author, "Optically Active Reference Compounds for Environmental Analysis Obtained by Preparative Enantioselective Gas Chromatography," 33 Angewandte Chemie International Edition 2085-2087, 1994

Biological Sciences and Biotechnology

  • Biochemistry
  • Bioconjugation
  • Cancer therapeutics
  • CAR-T cells
  • Immuno-oncology

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Drug conjugates
  • Drug delivery
  • Peptide therapeutics
  • Pharmacodynamics
  • Pharmacokinetics
  • Small molecule synthesis
  • Small molecules

Diagnostics and Medical Devices

  • Biosensors
  • Diagnostics

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Green chemistry
  • Materials chemistry
  • Organic chemistry
  • Polymers
  • Polymorph
  • Process chemistry
  • Supramolecular chemistry

Engineering and Technology

  • Materials Science

Miscellaneous

  • Food science
  • Formulations
  • Infectious diseases
  • Ophthalmology
Technical Fluency

Biological Sciences and Biotechnology

  • Biochemistry
  • Bioconjugation
  • Cancer therapeutics
  • CAR-T cells
  • Immuno-oncology

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Drug conjugates
  • Drug delivery
  • Peptide therapeutics
  • Pharmacodynamics
  • Pharmacokinetics
  • Small molecule synthesis
  • Small molecules

Diagnostics and Medical Devices

  • Biosensors
  • Diagnostics

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Green chemistry
  • Materials chemistry
  • Organic chemistry
  • Polymers
  • Polymorph
  • Process chemistry
  • Supramolecular chemistry

Engineering and Technology

  • Materials Science

Miscellaneous

  • Food science
  • Formulations
  • Infectious diseases
  • Ophthalmology
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Learn More
Alerts
Continued Scrutiny of Genus Claims: The Written Description and Enablement Requirements for Broad and Previously Undisclosed Subgenera
Executive Summary
Learn More
View All
Recent Events
Affiliated Programs
BioTools Innovator 2025 Capstone Event
Wilson Sonsini is proud to be an event sponsor for the Biotools Innovator Capstone Event on November 18th. The BioTools Innovator Capstone is the premier showcase for innovation in life science tools and diagnostics, bringing together leading pharma and biotech startups to present their groundbreaking technologies to a panel of judges, including Wilson Sonsini partners, Eric Hsu, Ingo Hardt, Marty Waters, and Bu Yin.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.